Cap analogs are used to cap the 5' end of mRNA in an in vitro synthesis reaction of mRNA. lt can replace the natural mRNA cap structure, and have the function of increasing mRNA stability and decrease immunogenicity. At present, mRNA capping is mainly carried out by in vitro transcription, in which mRNA is prepared by one-step method of co-transcription with cap analogues, which is relatively simple in process and quality control, and is the preferred method for mRNA preparation

The development of a new cap analogue product with independent intellectual property rights will provide the mRNA industry with cost-effective mRNA preparation raw materials and promote the development of the mRNA industry.

Hzymes Biotech provides a series of GMP-GRADE cap analogues with independent intellectual property rights for different applications in mRNA therapy.

Hzymes Cap Analogs: Innovation with Integrity

At Hzymes Biotech, we are proud to offer a series of cap analogs developed with independent intellectual property rights, designed to meet the highest standards in mRNA research and therapeutics. Our cap analogs provide researchers and manufacturers with reliable, cost-effective, and GMP-grade solutions tailored for clinical and preclinical applications.

By developing our own formulations, we not only reduce dependency on global supply chains but also make mRNA technologies more accessible — accelerating the pace of innovation and delivery.

Key Features of Hzymes Cap Analogs

• ✅ GMP-Grade: comprehensive quality control standard with high consistency between batches
• ✅ Ultra-Pure: Our cap analogs exhibit high purity with ultra-low metal residue, reducing toxicity and improving therapeutic performance.
• ✅ With Intellectual property rights.

Driving Innovation Across mRNA Applications

Hzymes cap analogs are used in a wide array of applications, including:

• 🧬 mRNA Vaccines: Delivering immunity against infectious diseases and cancers
• 🧪 Gene Therapies: Treating genetic disorders with high precision
• 🧫 In Vitro Research: Streamlining mRNA production workflows in labs and pilot plants

Whether you are working on next-generation cancer immunotherapies or global vaccine distribution, Hzymes’ cap analogs provide the quality and scalability needed to bring mRNA technologies to life.

Performance

Cap Your Success with Hzymes

In a world where speed and safety matter more than ever, Hzymes cap analogs empower researchers and manufacturers to produce stable, effective, and low-immunogenic mRNA with confidence. Our proprietary, GMP-grade products are designed to move your science forward — reliably, consistently, and ethically.